Suppr超能文献

[与肿瘤同种异体移植增强有关的抗原位点]

[Antigenic sites implicated in tumour allograft enhancement].

作者信息

Duc H T, Kinsky R G, Voisin G A

出版信息

Ann Immunol (Paris). 1977 Jan-Mar;128(1-2):19-20.

PMID:322579
Abstract

Allo-immune sera were prepared by injecting CBA mice with spleen or thymus cells, or by two consecutive skin grafts of A/Jax origin. When absorbed 6 to 8 times on glutaradahyde treated A/Jax red blood cells (RBC), these sera lost all their haemagglutinating activity (anti- "SD" antibodies, predominantly H-2D) While their cytotoxic activities on A/Jax lymphocytes (anti-LD antibodies, perdominantly Ia, H-2IC) were partially preserved. Antibodies (anti-"XD") eluted form A/Jax RBC treated with an 0.5 M NaCl--HCL glycincing activity of these preparations was tested using SaI (A/Jax) grafts in CBA mice. Our results suggest that SD antigens are the main target of the enhancing effect. Further results obtained with DBA/2 anti-EL4 (C57Bl/6) sera confirmed this interpretation. Experiments performed with anti-idiotype and anti-recognition structure sera using tumor allograft targets, did not reveal any clear cut effect. Their relevance in tumor enhancement appears therefore doubtful.

摘要

同种免疫血清通过给CBA小鼠注射脾脏或胸腺细胞,或通过连续两次移植A/Jax来源的皮肤来制备。当这些血清在经戊二醛处理的A/Jax红细胞(RBC)上吸收6至8次后,它们的所有血凝活性(抗“SD”抗体,主要是H-2D)丧失,而它们对A/Jax淋巴细胞的细胞毒性活性(抗-LD抗体,主要是Ia,H-2IC)部分保留。用0.5M NaCl-HCl从A/Jax RBC洗脱的抗体(抗“XD”),这些制剂的溶血活性用CBA小鼠中的SaI(A/Jax)移植进行测试。我们的结果表明SD抗原是增强作用的主要靶点。用DBA/2抗EL4(C57Bl/6)血清获得的进一步结果证实了这一解释。使用肿瘤同种异体移植靶标用抗独特型和抗识别结构血清进行的实验未显示任何明确的效果。因此它们在肿瘤增强中的相关性似乎值得怀疑。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验